Xilio Therapeutics (NASDAQ: XLO) reported fourth-quarter results that exceeded both revenue and earnings expectations. Revenue increased compared to a year earlier.
Earnings per share for the fourth quarter were $0.81, contrasting with the anticipated loss of $0.12 per share. This marks a notable improvement from the prior year’s performance.
The company reported revenue of $13.69 million for the fourth quarter, surpassing the analysts’ estimate of $7.96 million and showing an increase from $1.72 million a year earlier.
For the full year, collaboration and license revenue reached $43.8 million, up from $6.3 million last year. Research and development expenses were $56.0 million, compared to $41.2 million a year earlier. The net loss for 2025 was $35.0 million, compared to $58.2 million last year.
XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, is on track for an IND submission in mid-2026 and Phase 1 initiation in the second half of 2026.
The company is advancing a potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1, with plans to present new preclinical data at AACR for a program targeting CLDN18.2.
René Russo, Pharm.D., president and chief executive officer of Xilio, stated, “As we enter 2026, we are well-positioned to leverage our clinically validated masking technology to continue advancing our next generation of multi-specific I-O therapies toward the clinic.”
 reported fourth-quarter revenue of $13.69 million, exceeding the analysts' estimate of $7.96 million.){kind=link}